drugset / Trial / NCT00304278
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
Phase 2
Completed
21 enrolled
Southern Illinois University
Genentech, Inc. · collabOSI Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
Timeline
- Start
- 2006-03
- Primary completion
- 2015-05
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 150 mg/m2 | Other |
| Subject | Erlotinib | Small molecule | 150 mg | — |